These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9361690)

  • 21. Modulation of glucose and growth hormone responses to meals and exercise in type 1 diabetes by cholinergic muscarinic blockade.
    Ara J; Kang S; Creagh FM; Scanlon MF; Peters JR
    Diabet Med; 1994; 11(1):92-7. PubMed ID: 8181260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M; Procopio M; Grottoli S; Oleandri SE; Razzore P; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus.
    Martina V; Bruno G; Tagliabue M; Maccario M; Bertaina S; Zumpano E; Arvat E; Ghigo E; Camanni F
    Horm Metab Res; 1997 Apr; 29(4):180-3. PubMed ID: 9178028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG; Macfarlane P; Levitt NS; Millar RP
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced sensitivity to pirenzepine-induced blockade of growth hormone responses to arginine, exercise, and growth hormone-releasing hormone in type I diabetic subjects.
    Coiro V; Passeri M; Gardini E; Capretti L; Speroni G; Davoli C; Maffei ML; Fagnoni F; Bianconi L; Volpi R
    Metabolism; 1990 Jul; 39(7):668-75. PubMed ID: 2114512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
    Catalina PF; Mallo F; Andrade MA; García-Mayor RV; Diéguez C
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3663-7. PubMed ID: 9768681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aspects of the neuroendocrine control of somatotropic function in calorically restricted dogs and patients with eating disorders: studies with cholinergic drugs.
    Müller EE; Rolla M
    Psychiatry Res; 1996 Apr; 62(1):51-63. PubMed ID: 8739115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.
    Villas-Boas Weffort RF; Ramos-Dias JC; Chipoch C; Lengyel AM
    Metabolism; 1997 Jun; 46(6):706-10. PubMed ID: 9186309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M; Bossoni S; Alí A; Doga M; Reimondo G; Milani G; Peretti P; Manelli F; Angeli A; Giustina A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjects.
    Massara F; Ghigo E; Demislis K; Tangolo D; Mazza E; Locatelli V; Müller EE; Molinatti GM; Camanni F
    Neuroendocrinology; 1986; 43(6):670-5. PubMed ID: 3093909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
    Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Galanin abolishes the inhibitory effect of cholinergic blockade on growth hormone-releasing hormone-induced secretion of growth hormone in man.
    Chatterjee VK; Ball JA; Proby C; Burrin JM; Bloom SR
    J Endocrinol; 1988 Feb; 116(2):R1-2. PubMed ID: 2450944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep-related growth hormone release in young patients with insulin-dependent diabetes mellitus.
    Page MD; Koppeschaar HP; Dieguez C; Gibbs JT; Hall R; Peters JR; Scanlon MF
    Clin Endocrinol (Oxf); 1987 Mar; 26(3):355-9. PubMed ID: 3652479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An inhibition of the hypothalamic somatostatinergic tone is not the cause of the enhanced growth hormone response to growth hormone-releasing hormone in patients with liver cirrhosis.
    Fanciulli G; Tomasi PA; Giusti M; Bertoncelli A; Deplano A; Garrucciu G; Delitala G
    Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):148-51. PubMed ID: 18095239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic treatment with pirenzepine decreases growth hormone secretion in insulin-dependent diabetes mellitus.
    Martina V; Maccario M; Tagliabue M; Corno M; Camanni F
    J Clin Endocrinol Metab; 1989 Feb; 68(2):392-6. PubMed ID: 2918051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholinergic muscarinic receptor blockade suppresses arginine- and exercise-induced growth hormone secretion in type I diabetic subjects.
    Arends J; Wagner ML; Willms BL
    J Clin Endocrinol Metab; 1988 Feb; 66(2):389-94. PubMed ID: 3339112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The somatostatin analog octreotide inhibits the secretion of growth hormone (GH)-releasing hormone, thyrotropin, and GH in man.
    Masuda A; Shibasaki T; Kim YS; Imaki T; Hotta M; Demura H; Ling N; Shizume K
    J Clin Endocrinol Metab; 1989 Oct; 69(4):906-9. PubMed ID: 2506217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus.
    Crowne EC; Samra JS; Cheetham T; Watts A; Holly JM; Dunger DB
    Metabolism; 1998 Jan; 47(1):31-8. PubMed ID: 9440474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of residual C-peptide secretion on nocturnal serum TSH peak in well-controlled diabetic patients.
    Coiro V; Volpi R; Marchesi C; Capretti L; Speroni G; Caffarri G; Chiodera P
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):305-10. PubMed ID: 9373451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 24-hour secretion of growth hormone (GH), insulin-like growth factors-I and -II (IGF-I, -II), prolactin (PRL) and thyrotropin (TSH) in young adults of normal and tall stature.
    Stratakis CA; Mastorakos G; Magiakou MA; Papavasiliou EC; Panitsa-Faflia C; Georgiadis E; Batrinos ML
    Endocr Res; 1996 Aug; 22(3):261-76. PubMed ID: 8875138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.